Lacosamide exposure
Most patients (74 [71.8%]) initiated lacosamide as adjunctive IV treatment upon enrolment, 26 (25.2%) received IV lacosamide as a replacement for prescribed oral lacosamide from a commercial supply, and three (2.9%) patients received IV lacosamide as a replacement for oral lacosamide received in another open‐label, long‐term trial. The mean overall duration of exposure to IV lacosamide was 1.18 days (median: 1 day; range: 1‐5 days; standard deviation [SD]: 0.71). The mean duration of exposure was 1.10 days (range: 1.0‐2.0 days; SD: 0.31) for patients ≥1 month to <8 years of age, and 1.25 days (range: 1.0–5.0 days; SD: 0.93) for patients ≥8 years to <17 years of age. Most (81 [78.6%]) patients had a target IV lacosamide infusion duration of 30‐60 minutes rather than 15‐30 minutes (22 [21.4%]). Seventy‐nine (76.7%) patients had one IV lacosamide infusion, 20 (19.4%) had two infusions, one (1.0%) had three infusions, and three (2.9%) had 10 infusions (Figure Number of infusions by cohort and overall (SS‐IV). SS‐IV, intravenous safety set